Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
ConclusionThese results from an integrated analysis support a favorable benefit-risk profile of ibrutinib in patients with CLL/SLL and MCL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Atrial Fibrillation | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hypertension | Leukemia | Lymphoma | Myeloma | Study